Supplementary Information

for

Uranyl-catalysed C-H Alkynylation and Olefination

Yu Mao, Yeqing Liu, Lei Yu, Shengyang Ni, Yi Wang* and Yi Pan

State Key Laboratory of Coordination Chemistry, Jiangsu Key Laboratory of Advanced Organic Materials, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, China

E-mail: yiwang@nju.edu.cn;

Supplementary Methods

General Methods. All reactions were performed in flame-dried glassware with magnetic stirring bar and sealed with a rubber septum. The solvents were distilled by standard methods. Reagents were obtained from commercial suppliers and used without further purification unless otherwise noted. Silica gel column chromatography was carried out using silica Gel 60 (230-400 mesh). Analytical thin layer chromatography (TLC) was done using silica Gel (silica gel 60 F254). TLC was performed on pre-coated silica gel plated, using short-wave UV light as the visualizing agent, and phosphomolybdic acid, *p*-anisaldehyde, or KMnO₄ and heat as developing agents. NMR experiments were measured on a Bruker AVANCE III-400 or 500 spectrometer and carried out indeuterochloroform (CDCl₃) ¹H NMR and ¹³C NMR spectra were recorded at 400 MHz or 500 MHz and 100 MHz or 125 MHz spectrometers respectively. 19F NMR spectra were recorded at 376 MHz or 470 MHz spectrometers. Chemical shifts are reported as δ values relative to internal TMS (δ 0.00 for ¹H NMR), chloroform (δ 7.26 for ¹H NMR), chloroform (δ 77.00 for ¹³C NMR). The following abbreviations are used for the multiplicities: s: singlet, d: doublet, dd:doublet of doublet, t: triplet, q: quadruplet, m: multiplet, br: broad signal for proton spectra; Coupling constants (J) are reported in Hertz (Hz). Melting points were uncorrected. HRMS were recorded on a Bruker microTOF-Q111. GC-MS spectra were performed on Shimadzu QP2010 (EI Source). A borosilicate glass tube was used as a reaction tube. The reaction mixture was irradiated with two Kessil LEDs (Saltwater Aquarium Light A360WE Series Tuna Blue; Rating: 19VDC 90W Max http://www.kessil.com/products/saltwater_A360.php) from 10 cm away. The emission spectrum of the lamp is shown below:



Supplementary Figure 1. Emission spectrum of the lamp

We have not used any filters. Unless otherwise noted, all reagents were weighed and handled in air, and all reactions were underargon.

Medium-sized screw-cap test tubes (8 mL) were used for all 0.20 mmol scale reactions: Fisher 13 x 100 mm tubes (Cat. No.1495935C), Cap with Septa: Thermo Scientific ASM PHN CAP w/PTFE/SIL (Cat. No.03378316)





(left) 0.20 mmol scale reactions (right) gram scale reactions

Synthesis of Starting Materials.

Synthesis of Alkynyl Bromides (Procedure A)

Alkynyl bromides were prepared according to a previously reported procedure¹. Terminal alkynes (5.00 mmol, 1.00 equiv) was dissolved in acetone (30 mL). N-bromosuccinimide (5.80 mmol, 1.16 equiv) was added, followed by silver nitrate (0.50 mmol, 0.1 equiv). The resulting mixture was stirred at room temperature for 3 h and it was then poured onto ice. After ice being allowed to melt, the aqueous layer was extracted with pentane (3 x 30 mL, ethyl acetate instead of pentane if precipitate). The combined organic layers were dried over MgSO₄ , filtered and concentrated in vacuo to afford bromoalkynes. If necessary, the product could be purified by column chromatography or recrystallization.

The bromoalkynes shown below were prepared according to Procedure A.



Synthesis of Alkenyl Bromides

Method A (Procedure B)

Alkenyl bromides were prepared according to a previously reported procedure². A round-bottomed flask was charged with cinnamic acid (1.00 mmol, 1.00 equiv), N-bromosuccinimide (1.05 mmol, 1.05 equiv), Manganese(II) acetate tetrahydrate (0.20 mmol, 0.20 equiv), 2 mL of water and 2 mL of acetonitrile. The reaction mixture was stirred at room temperature and monitored by TLC analysis. After total conversion of substrates, acetonitrile was evaporated. The mixture was extracted by

diethyl ether (2 mL x 3). The combined organic extracts were washed with brine, dried over anhydrous Na_2SO_4 . After evaporation of the solvent, the residue was purified by column chromatography to give the product.

The bromoalkynes shown below were prepared according to **Procedure B**.



Method B (Procedure C)



(2-bromoethene-1,1-diyl)dibenzene was prepared according to a previously reported procedure³. To a suspension of 1, 1-diphenylethene (2.00 mmol, 1.00 equiv) in AcOH (2 mL) was added N-bromosuccinimide (2.00 mmol, 1.00 equiv). The resulting mixture was stirred at 70 °C for 4 h. After cooling down to room temperature naturally, the reaction was neutralized by slowly adding NaOH/NaHCO₃ (1:1) and extracted with ethyl acetate (3 x 10 mL). The combined organic layers were dried over MgSO₄ and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (petroleum ether / ethyl acetate 100:1) to afford 2,2-diarylvinyl bromides. (97%, 0.52 g).

Synthesis of Allyl Bromides

Method A (Procedure D)

$$Ar \xrightarrow{NBS}_{TsOH} Ar \xrightarrow{Br} Br$$

Allyl bromides were prepared according to a previously reported procedure⁴. In an oven dried flask 1-methylethylenebenzene (5.00 mmol, 1.00 equiv.) was taken and to this dry tetrahydrofuran (15 mL) was added. To the resulting solution N-bromosuccinimide (5.25 mmol, 1.05 equiv.) and *p*-toluenesulfonic acid (0.50 mmol, 0.10 equiv.) was added and the solution was refluxed at 100 \degree for 4 h. Reaction

mixture was cooled to rt and the reaction mixture was taken in petroleum ether (15 mL/mmol), washed with water (15 mL x 3). Organic phase was dried over Na_2SO_4 , concentrated under reduced pressure to obtain a yellow oil. Purification by column chromatography using petroleum ether as eluent afforded the product.

The allyl bromides shown below were prepared according to Procedure D.



Method B (Procedure E)



Bromo carvone was prepared according to a previously reported procedure⁵. A solution of (S)-carvone (30.0 mmol, 1.00 equiv.) and sodium acetate (22.0 mmol, 0.73 equiv.) in 45 mL of a mixture of CH_2Cl_2 and acetic acid (40 mL, 3 : 2) was cooled in an ice bath. To the magnetically stirring solution was added N-bromosuccinimide (36.0 mmol, 1.20 equiv.) in small portions over a period of 90 min. The reaction mixture was stirred at room temperature for 5 h, diluted with 50 mL of CH_2Cl_2 , washed successively with water (3 x 30 mL), aqueous NaHCO₃ (3 x 30 mL), and brine, and dried over anhydrous Na₂SO₄. Evaporation of the solvent and purification of the residue on silica gel with 1:3 ethyl acetate-hexane as eluent furnished allyl bromide (1.25 g, 40%) as an oil.

Synthesis of Amide

Synthesis of 2,2-dimethyl-1-(piperidin-1-yl)propan-1-one (Procedure F)



2,2-dimethyl-1-(piperidin-1-yl)propan-1-one was prepared according to a previously reported procedure⁶. To a 100 ml flask charged with a magnetic stirring bar and piperidine (0.92 mL, 1.0 equiv., 10 mmol) was added. Dichloromethane (50 ml, 0.2 M) was added and the mixture was cooled to $0 \,^{\circ}$ C with an ice bath. Triethylamine (2.80

ml, 2.0 equiv., 20 mmol) was added in one portion. Pivaloyl chloride (1.35 ml, 1.1 equiv., 11 mmol) was then added dropwise and the reaction was stirred for 2 h before quenching with sat. NaHCO₃. The organic layer was separated, washed with brine, dried over anhydrous magnesium sulfate, and filtered to a yellowish oil (1.6 g, 95%), which was used without further purification.

Synthesis of Methyl acetyl-L-prolinate (Procedure G)



Methyl acetyl-*L*-prolinate was prepared according to a previously reported procedure⁷. Into a flask were added methyl *L*-prolinate hydrochloride (490 mg, 2.96 mmol, 1.0 equiv), dichloromethane (30 mL, 0.1 M), and 4-(dimethylamino)pyridine (90 mg, 0.74 mmol, 0.25 equiv). The flask was capped with a rubber septum and maintained under a nitrogen atmosphere. To the flask were added triethylamine (1.64 mL, 11.86 mmol, 4.0 equiv) and acetic anhydride (0.56 mL, 5.92 mmol, 2.0 equiv). The mixture was stirred (2.5 h), diluted with dichloromethane (80 mL), washed with sodium carbonate (10% aqueous, 80 mL) and citric acid (10% aqueous, 80 mL), and dried with sodium sulfate. Volatiles were removed under reduced pressure, and the crude material was purified by column chromatography (silica gel, EtOAc) to yield acetamide (313 mg, 62%).

Optimization Tables

	Me Ac−N + Br — Ph - (5 equiv.) (1 equiv.)	UO ₂ (NO ₃)•6H ₂ O (8 mol%) Solvent (0.1 M) 452 nm LED (60 W) 25 °C, 24 h	Ac-NPh
Entry		Solvent	Yield ^a (%)
1	acetonitrile		23
2	acetone		26
3	benzene		28
4	methanol		0
5	dime	thyl sulfoxide	0

Supplementary Table 1. Optimization of Solvent

^a Yields were determined by GC-FID using cyclododecane as internal standard.

Supplementary Table 2. Optimization of Base

	Ac - N - H + Br - Ph (5 equiv.) (1 equiv.)	UO ₂ (NO ₃)•6H ₂ O (8 mol%) Base (1 equiv.) MeCN (0.1 M) 452 nm LED (60 W) 25 °C, 24 h	Ac-NPh
Entry		Base	Yield ^a (%)
1		K_2CO_3	8
2		K ₃ PO ₄	0
3		Et ₃ N	0
4		LiOH H ₂ O	0

^a Yields were determined by GC-FID using cyclododecane as internal standard.

	$Ac - N \underbrace{H}_{H}^{Me} + Br - H$ (x equiv.) (1 equiv.)	UO ₂ (NO ₃)•6H ₂ O (8 mol%) MeCN (0.1 M) 452 nm LED (60 W) 25 °C, 24 h	Ac-NPh
Entry	Μ	laterial Ratio	Yield(%)
1	x = 5		23
2	x = 10		31
3	x = 20		49
4	DM	IAc as solvent	73

Supplementary Table 3. Optimization of Material Ratio

^a Yields were determined by GC-FID using cyclododecane as internal standard.

Supplementary Table 4. Optimization of Light Sources

	$Ac-N H + Br - H$ $(0.1 \text{ M}) \qquad (1 \text{ equiv.})$	UO ₂ (NO ₃)•6H ₂ O (8 mol%) 452 nm LED 25 °C, 24 h	Ac-NPh	
Entry	L	ight sources		Yield(%)
1	30 W blue LEDs			59
2	90 W blue LEDs			72
3	-	in darkness		0

^a Yields were determined by GC-FID using cyclododecane as internal standard.

	UO ₂ (NO ₃)•6H ₂ O (8 mol%) Me ligand (10 mol%) Me	
	Ac - N + Br - Ph + 452 nm LED (60 W) Ac - N + 600 cm LED (600 W) Ac - N + 6000 c	—Ph
	$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	
Entry	Ligands	Yield(%)
1	L1	7
2	L2	74
3	L3	98
4	L4	81
5	L5	86

Supplementary Table 5. Optimization of Ligands

^a Yields were determined by GC-FID using cyclododecane as internal standard.

Supplementary Table 5. Optimization of Catalylst Quantity

	Me Ac−N + Br───Ph − (0.1 M) (1 equiv.)	UO ₂ (NO ₃)•6H ₂ O pbi 452 nm LED (60 W) air, 25 °C, 24 h	Ac-NPh
Entry	Catalylst Quantity		Yield(%)
1	[UO ₂] (8 mo	l%) & pbi (10 mol%)	98
2	[UO ₂] (4 mo	ol%) & pbi (5 mol%)	51

^a Yields were determined by GC-FID using cyclododecane as internal standard.

General Procedure

Procedure for C-H Alkynylation, Alkenylation and Allylation



Method A (Procedure H)

Uranyl nitrate hexahydrate (8.0 mg, 8 mol%), 2-(2-pyridyl)benzimidazole (pbi) (3.9 mg, 10 mol%) and the bromide (if solid, 0.2 mmol, 1.0 equiv.) were added into a screw-cap test tube with stirring bar. The alkyl source (2 mL, 0.1 M) was injected into the tube, followed with the bromide (if liquid, 0.2 mmol, 1.0 equiv.). Afterwards, the tube was set between two lamps (10 cm away from the lamp, 60 W each) and stirred at room temperature (with a fan to cool down the reaction) for 24 h. The mixture was diluted with ethyl acetate and washed with saturated NaHCO₃ (10 mL), water (10 mL x 3) and brine (10 mL). The organic layer was dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The crude material was purified by column chromatography to afford the corresponding product.

Method B (Procedure I)

Uranyl nitrate hexahydrate (8.0 mg, 8 mol%) and 2-(2-pyridyl)benzimidazole (3.9 mg, 10 mol%) were added into a screw-cap test tube with stirring bar. The bromide (0.2 mmol, 1.0 equiv.) and the alkyl source (1 mmol, 5.0 equiv.) were dissolved in benzene (1 mL, 0.2 M) and the solution was injected into the tube. Afterwards, the tube was set between two lamps (10 cm away from the lamp, 60 W each) and stirred at room temperature (with a fan to cool down the reaction) for 24-96 h. The mixture was diluted with ethyl acetate and washed with saturated NaHCO₃ (10 mL), water (10 mL x 3) and brine (10 mL). The organic layer was dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The crude material was purified by column chromatography to afford the corresponding product.

Procedure for One-pot Alkynylation with Terminal Alkynes (Procedure J)



In a screw-cap test tube, silver nitrate (3.4 mg, 10 mol%), N-bromosuccinimide (41.3 mg, 1.16 equiv.) and phenylacetylene (22 μ L, 1.0 equiv.) were dissolved in N,N-dimethylacetamide (2 mL, 0.1 M). The mixture was stirred for 1 h and then uranyl nitrate hexahydrate (8.0 mg, 8 mol%) and 2-(2-pyridyl)benzimidazole (3.9 mg, 10 mol%) were added. Afterwards, the tube was set between two lamps (10 cm away from the lamp, 60 W each) and stirred at room temperature (with a fan to cool down the reaction) for 24 h. The mixture was diluted with ethyl acetate and washed with saturated NaHCO₃ (10 mL), water (10 mL x 3) and brine (10 mL). The organic layer was dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The crude material was purified by column chromatography (silica, 50% ethyl acetate / petroleum ether) to afford the propargyl amide (colorless oil, 25.1 mg, 67%).

Procedure for Alkynylation with Aldehyde (Dibromoethene)

Synthesis of dibromoethene (Procedure K)



Dibromoethene was prepared according to a previously reported procedure⁸. Carbon tetrabromide (1.33 g, 4.0 mmol), 4-benzyloxybenzaldehyde (424 mg, 2.0 mmol) and triphenylphosphine (2.10 g, 8.0 mmol) was stirred at 0 $\$ in dichloromethane (6 mL). The ice bath was removed, and the reaction mixture was stirred at room temperature overnight. The reaction mixture was quenched with pentane (30 mL) and filtered through a silica plug (Et₂O). The solvent was removed under reduced pressure and the corresponding dibromoethene was isolated by flash column chromatography (5% ethyl acetate / petroleum ether) as a white solid (0.67 g, 91%).

Alkynylation with dibromoethene (Procedure L)



Uranyl nitrate hexahydrate (8.0 mg, 8 mol%), 2-(2-pyridyl)benzimidazole (pbi) (3.9 mg, 10 mol%) and the dibromoethene (58.7 mg, 0.2 mmol, 1.0 equiv.) were added with stirring into a screw-cap test tube a bar. 2-(tert-butyl)-1,1,3,3tetramethylguanidine (40 µL, 1.0 equiv.) were dissolved in N,N-dimethylacetamide (2 mL, 0.1 M) and the solution was injected into the tube. Afterwards, the tube was set between two lamps (10 cm away from the lamp, 60 W each) and stirred at room temperature (with a fan to cool down the reaction) for 24 h. The mixture was diluted with ethyl acetate and washed with water (10 mL x 3) and brine (10 mL). The organic layer was dried over anhydrous Na₂SO₄, and concentrated under reduced pressure. The crude material was purified by column chromatography to afford the corresponding propargyl amide.

Flowing Reaction

Flowing reaction is carried out with a homemade setup consisting of peristaltic pump (CM1000; purchased from Baoding Chuang Rui Precision Pump Co., Ltd), annular capillary tube (PTEF, ID 0.8 mm, ED 1.6 mm, length 40 m, volume 20 mL) and two Kessil LEDs (Saltwater Aquarium Light A360WE Series Tuna Blue; Rating: 19VDC 90W Max).





We selected (bromoethynyl)benzene to react in continuous flow in 2.0 mmol scale. Uranyl nitrate hexahydrate (80.3 mg, 8 mol%), 2-(2-pyridyl)benzimidazole (pbi) (39.0 mg, 10 mol%), (bromoethynyl)benzene (362 mg, 2.0 mmol, 1.0 equiv.) and cyclododecane (84.2 mg, 0.25 equiv., internal standard) were dissolved in N,N-dimethylacetamide (20 mL). The yellow mixture was then transferred into a sample bottle (wrapped in aluminum foil). Next, the reaction mixture was flowing under the irradiation of two 60 W blue LEDs (distance app. 10.0 cm) in the mode of extraction at the speed of 0.33 mL/min. After 1 h, the sample would be completely transferred to the reservoir bottle (wrapped in aluminum foil). The position of two bottles could be exchanged so the reaction time could be extended. The products and the crude yields were monitored by GC-FID and GC-MS. The comparison of reaction rate with conventional reaction was shown below.



Supplementary Figure 3. Comparison between conventional and flowing reactor

Synthesis of the Uranyl Nitrate Peroxide Complex

$$UO_2(NO_3)_2 \bullet 6H_2O + pbi$$

 452 nm LED $[UO_2(pbi)(NO_3)]_2(O_2) \bullet 2Me_2CO$
air, 25 °C, 1 h

Uranyl hexahydrate (25.1)mg, 0.05 mmol, 1.0 equiv.) nitrate and 2-(2-pyridyl)benzimidazole (pbi) (9.8 mg, 1.0 equiv.) were dissolved in acetone (2 mL, 0.1 M) in a screw-cap test tube with a stirring bar. The tube was set between two lamps (10 cm away from the lamp, 60 W each) and stirred under ambient conditions. The tube was pierced by a syringe needle and the solvent volatilized slowly for 1-2 weeks. The orange supernatant was decanted and the yellow crystals were harvested and dried under vacuum. Single crystals for structure determination were isolated manually from the initial crude precipitate. (10.5 mg, 35% based on U).

X-ray crystallography data for Uranyl Nitrate Peroxide



Supplementary Figure 4. X-ray structure of uranyl nitrate peroxide

Supplementary Table 6 Crystal data and structure refinement

Identification code	Compound 52
Empirical formula	$C_{30}H_{30}N_8O_{14}U_2\\$
Formula weight	1202.68
Temperature/K	193
Crystal system	orthorhombic
Space group	$Pca2_1$

a/Å	14.6321(10)
b/Å	15.2595(7)
c/Å	16.1553(9)
α/	90
β/	90
$\gamma/$	90
Volume/Å ³	3607.1(4)
Z	4
$\rho_{calc}g/cm^3$	2.215
μ/mm^{-1}	9.046
F(000)	2248.0
Crystal size/mm ³	0.15 imes 0.12 imes 0.1
Radiation	MoKa ($\lambda = 0.71073$)
2Θ range for data collection/	4.608 to 58.134
Index ranges	$\text{-18} \le h \le 17, \text{-15} \le k \le 20, \text{-19} \le l \le 19$
Reflections collected	22885
Independent reflections	8231 [R_{int} = 0.0743, R_{sigma} = 0.0846]
Data/restraints/parameters	8231/253/491
Goodness-of-fit on F ²	1.007
Final R indexes [I>= 2σ (I)]	$R_1 = 0.0572$, $wR_2 = 0.1347$
Final R indexes [all data]	$R_1 = 0.0721$, $wR_2 = 0.1456$
Largest diff. peak/hole / e Å ⁻³	5.90/-3.33
Flack parameter	0.038(10)

Characterization Data for Products

General Information

NMR experiments were measured at room temperature. All the asymmetric tertiary amide derivatives are mixtures of two conformational products, giving a splitting of the signal in both ¹H NMR and ¹³C NMR spectra.

Compound 3



Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 1:1) afforded 36.0 mg (96%).

Physical State: colorless oil.

 $R_f = 0.40$ (petroleum ether/ethyl acetate = 1:1).

¹**H NMR (400 MHz, CDCl₃):** δ 7.46 – 7.36 (m, 2H), 7.36 – 7.24 (m, 3H), 4.44/4.24 (s, 2H), 3.11/3.03 (s, 3H), 2.20/2.11 (s, 3H) ppm.

¹³C NMR (101 MHz, CDCl₃): δ 170.6, 170.4, 131.8, 131.8, 128.7, 128.4, 128.4, 128.3, 122.8, 122.3, 84.6, 84.3, 83.7, 83.2, 41.2, 36.8, 35.2, 33.4, 21.8, 21.6 ppm. This compound was previously reported⁹.

Compound 4



Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 2:1) afforded 19.1 mg (52%).

Physical State: colorless oil.

 $R_f = 0.26$ (petroleum ether/ethyl acetate = 2:1).

¹H NMR (400 MHz, CDCl₃): δ 8.23 – 8.02 (m, 1H), 7.50 – 7.37 (m, 3H), 7.41 – 7.25 (m, 2H), 4.50 – 4.17 (m, 2H), 3.18 – 2.97 (m, 3H) ppm.
¹³C NMR (126 MHz, CDCl₃):δ 162.4, 162.2, 131.9, 131.8, 128.9, 128.6, 128.5, 128.4, 122.5, 122.1, 85.5, 84.2, 82.9, 82.6, 40.1, 34.0, 34.0, 29.6 ppm. This compound was previously reported¹¹.

Compound 5



Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 2:1) afforded 10.5 mg (29%).

Physical State: colorless oil.

 $R_f = 0.34$ (petroleum ether/ethyl acetate = 2:1).

¹**H NMR (400 MHz, CDCl₃):** δ 7.57 – 7.52 (m, 2H), 7.43 – 7.33 (m, 3H), 3.29 (s, 3H), 3.03 (s, 3H) ppm.

¹³C NMR (126 MHz, CDCl₃): δ 149.2, 132.3, 130.0, 128.5, 121.6, 90.2, 81.6, 38.4, 34.2. ppm.

This compound was previously reported¹¹.

Compound 6

Ac N Åс

Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 1:1) afforded 21.1 mg (49%).

Physical State: colorless oil.

 $R_f = 0.35$ (petroleum ether/ethyl acetate = 1:1).

¹**H NMR (400 MHz, CDCl₃):** δ 7.44 – 7.39 (m, 2H), 7.34 – 7.27 (m, 3H), 4.72 (s, 2H), 2.54 (s, 6H) ppm.

¹³C NMR (101 MHz, CDCl₃): δ 172.5, 131.8, 128.7, 128.3, 122.1, 83.8, 83.5, 34.6, 26.4 ppm.

HRMS (**ESI-TOF**): calculated for C₁₃H₁₃NO₂ [M+Na]⁺: 238.0839, found: 238.0840.

Compound 7



Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 1:1) afforded 34.9 mg (81%).

Physical State: colorless oil.

 $R_f = 0.44$ (petroleum ether/ethyl acetate = 1:1).

¹**H NMR (400 MHz, CDCl₃):** δ 7.47 – 7.37 (m, 2H), 7.37 – 7.28 (m, 3H), 5.74/4.84 (q, *J* = 6.9 Hz, 1H), 3.69 – 3.34 (m, 2H), 2.18/2.14 (s, 3H), 1.55/1.43 (d, *J* = 7.0 Hz, 3H), 1.35/1.26 (t, *J* = 7.1 Hz, 3H) ppm.

¹³C NMR (101 MHz, CDCl₃): δ 169.9, 169.5, 131.7, 131.7, 128.7, 128.5, 128.4, 128.4, 123.0, 122.5, 89.0, 83.7, 46.6, 42.0, 39.9, 38.1, 29.8, 21.9, 21.8, 21.1, 16.3, 14.7 ppm.

HRMS (**ESI-TOF**): calculated for C₁₄H₁₇NO [M+Na]⁺: 238.1203, found: 238.1201.

Compound 8

Following **Procedure I** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 1:1) afforded 14.6 mg (42%).

Physical State: colorless oil.

 $R_f = 0.45$ (petroleum ether/ethyl acetate = 1:1).

¹**H NMR (400 MHz, CDCl₃):** δ 7.47 – 7.37 (m, 2H), 7.33 – 7.26 (m, 3H), 6.11 (s, 1H), 4.25 (d, *J* = 5.2 Hz, 2H), 2.02 (s, 3H) ppm.

¹³C NMR (101 MHz, CDCl₃): δ 170.0, 131.8, 128.5, 128.4, 122.6, 84.9, 83.4, 30.2, 23.1 ppm.

This compound was previously reported⁹.

Compound 9



Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 1:1) afforded 27.4 mg (69%).

Physical State: colorless oil.

 $R_f = 0.35$ (petroleum ether/ethyl acetate = 1:1).

¹**H NMR (400 MHz, CDCl₃):** δ 7.45 – 7.39 (m, 2H), 7.36 – 7.30 (m, 3H), 4.62 – 4.33 (m, 1H), 2.94 (s, 3H), 2.63 – 2.51 (m, 1H), 2.48 – 2.36 (m, 2H), 2.25 – 2.15 (m, 1H) ppm.

¹³C NMR (126 MHz, CDCl₃):δ 174.5, 131.8, 128.8, 128.5, 122.2, 86.5, 85.5, 52.0, 29.9, 28.2, 26.3 ppm.

This compound was previously reported¹¹.

Compound 10

Ρiv

Following **Procedure I** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 5:1) afforded 25.9 mg (48%).

Physical State: colorless oil.

 $R_f = 0.30$ (petroleum ether/ethyl acetate = 5:1).

¹**H NMR (400 MHz, CDCl₃):** δ 7.48 – 7.38 (m, 2H), 7.36 – 7.26 (m, 3H), 5.72 (s, 1H), 4.21 (d, *J* = 13.4 Hz, 1H), 3.35 (s, 1H), 2.02 – 1.85 (m, 2H), 1.78 – 1.66 (m, 3H), 1.44 (qt, *J* = 13.2, 4.1 Hz, 1H), 1.31 (s, 9H) ppm.

¹³C NMR (101 MHz, CDCl₃): δ 176.2, 131.9, 128.4, 128.3, 123.1, 87.7, 84.7, 77.5, 77.2, 76.8, 45.0, 42.4, 39.0, 31.1, 28.5, 26.1, 20.6 ppm.

HRMS (**ESI-TOF**): calculated for C₁₈H₂₃NO [M+Na]⁺: 292.1672, found: 292.1672.

Compound 11



Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (ethyl acetate) afforded 38.1 mg (88%).

Physical State: colorless oil.

 $R_f = 0.45$ (ethyl acetate).

¹**H NMR (400 MHz, CDCl₃):** δ 7.49 – 7.39 (m, 2H), 7.34 – 7.27 (m, 3H), 4.12 (s, 2H), 2.93 (s, 3H), 2.86 (s, 6H) ppm.

¹³C NMR (101 MHz, CDCl₃): δ 164.9, 131.8, 128.4, 128.3, 123.0, 85.2, 84.0, 41.1, 38.7, 36.4 ppm.

HRMS (**ESI-TOF**): calculated for C₁₃H₁₆N₂O [M+Na]⁺: 239.1155, found: 239.1154.

Compound 12



Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography

Physical State: colorless oil.

 $R_f = 0.56$ (dichloromethane/methanol = 10:1).

¹**H NMR (400 MHz, CDCl₃):** δ 7.43 – 7.36 (m, 2H), 7.33 – 7.27 (m, 3H), 4.01 (d, J =

9.7 Hz, 2H), 2.78 (d, *J* = 8.9 Hz, 3H), 2.69 (d, *J* = 9.6 Hz, 12H) ppm.

¹³C NMR (101 MHz, CDCl₃): δ 131.7, 128.4, 128.3, 123.2, 86.2, 86.2, 83.9, 39.8, 39.7, 37.0, 37.0, 34.2, 34.2 ppm.

³¹P NMR (162 MHz, CDCl₃): δ 25.0.

HRMS (**ESI-TOF**): calculated for $C_{14}H_{22}N_3OP$ [M+Na]⁺: 302.1393, found: 302.1395.

Compound 13



Following **Procedure I** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 2:1) afforded 34.5 mg (49%).

Physical State: colorless oil.

 $R_f = 0.40$ (petroleum ether/ethyl acetate = 2:1).

¹**H NMR (400 MHz, CDCl₃):** δ 7.48 – 7.40 (m, 2H), 7.26 – 7.22 (m, 2H), 4.90 – 4.83 (m, 1H), 4.63 – 4.57 (m, 1H), 3.72 (s, 3H), 2.53 – 2.38 (m, 2H), 2.28 (s, 3H), 2.25 – 2.15 (m, 1H), 2.13 – 2.02 (m, 1H) ppm.

¹³C NMR (101 MHz, CDCl₃): δ 172.4, 170.0, 133.1, 131.7, 123.0, 121.0, 88.8, 82.9, 58.6, 52.4, 50.3, 32.6, 28.1, 22.4 ppm.

HRMS (**ESI-TOF**): calculated for $C_{16}H_{16}BrNO_3$ [M+Na]⁺: 372.0206, found: 372.0202.



Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 20:1) afforded 18.4 mg (49%).

Physical State: colorless oil.

 $R_f = 0.32$ (petroleum ether/ethyl acetate = 20:1).

¹**H NMR (400 MHz, CDCl₃):** δ 7.47 – 7.41 (m, 2H), 7.34 – 7.27 (m, 3H), 4.32 (s, 2H), 1.29 (s, 9H) ppm.

¹³C NMR (126 MHz, CDCl₃): δ 131.9, 128.3, 128.3, 123.2, 87.2, 84.9, 51.3, 29.9, 27.7 ppm.

This compound was previously reported¹³.

Compound 15

Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 20:1) afforded 17.9 mg (52%).

Physical State: colorless oil.

 $R_f = 0.42$ (petroleum ether/ethyl acetate = 20:1).

¹**H NMR (500 MHz, CDCl₃):** δ 7.47 – 7.39 (m, 2H), 7.35 – 7.27 (m, 3H), 4.81 (dd, *J* = 7.2, 4.9 Hz, 1H), 4.06 – 3.98 (m, 1H), 3.86 (td, *J* = 7.9, 5.4 Hz, 1H), 2.28 – 2.18 (m, 1H), 2.15 – 2.04 (m, 2H), 2.00 – 1.90 (m, 1H) ppm.

¹³C NMR (126 MHz, CDCl₃): δ 131.8, 128.4, 128.3, 122.9, 89.2, 84.6, 68.7, 68.1, 33.5, 25.6 ppm.

This compound was previously reported⁹.



Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 20:1) afforded 23.6 mg (63%).

Physical State: colorless oil.

 $R_f = 0.33$ (petroleum ether/ethyl acetate = 20:1).

¹H NMR (500 MHz, CDCl₃): δ 7.48 – 7.43 (m, 2H), 7.35 – 7.28 (m, 3H), 4.57 (dd, J = 8.5, 2.9 Hz, 1H), 3.94 (ddd, J = 11.5, 5.5, 2.4 Hz, 2H), 3.79 – 3.66 (m, 4H) ppm.
¹³C NMR (126 MHz, CDCl₃): δ 132.0, 128.8, 128.4, 122.1, 86.7, 84.4, 70.5, 66.6, 66.5, 65.9 ppm.

This compound was previously reported¹⁰.

Compound 17

Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 20:1) afforded 18.9 mg (51%).

Physical State: colorless oil.

 $R_f = 0.40$ (petroleum ether/ethyl acetate = 20:1).

¹**H NMR (400 MHz, CDCl₃):** δ 7.50 – 7.40 (m, 2H), 7.36 – 7.23 (m, 3H), 4.51 (dd, *J* = 7.9, 2.9 Hz, 1H), 4.16 – 3.97 (m, 1H), 3.59 (ddd, *J* = 11.7, 8.3, 3.3 Hz, 1H), 1.99 – 1.83 (m, 2H), 1.85 – 1.72 (m, 1H), 1.70 – 1.53 (m, 3H) ppm.

¹³C NMR (101 MHz, CDCl₃): δ 131.9, 128.4, 128.3, 122.9, 88.2, 85.3, 67.6, 66.8, 32.3, 25.8, 22.0 ppm.

This compound was previously reported¹³.



Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 20:1) afforded 19.3 mg (51%).

Physical State: colorless oil.

 $R_f = 0.35$ (petroleum ether/ethyl acetate = 20:1).

¹H NMR (400 MHz, CDCl₃): δ 7.47 – 7.42 (m, 2H), 7.31 (dd, J = 5.2, 2.1 Hz, 3H), 4.41 (dd, J = 7.3, 4.0 Hz, 1H), 3.73 – 3.60 (m, 2H), 3.53 (s, 3H), 3.45 (s, 3H) ppm.
¹³C NMR (101 MHz, CDCl₃): δ 132.0, 128.7, 128.4, 122.5, 87.0, 85.0, 75.1, 71.2, 59.5, 57.0 ppm.

This compound was previously reported¹⁰.

Compound 19



Following **Procedure I** on 0.20 mmol scale, using 40 equiv. of cyclooctane, reaction for 96 h. Purification by column chromatography (petroleum ether) afforded 23.4 mg (55%).

Physical State: colorless oil.

 $R_f = 0.65$ (petroleum ether).

¹**H NMR (400 MHz, CDCl₃):** δ 7.43 – 7.35 (m, 2H), 7.32 – 7.21 (m, 3H), 2.79 (tt, *J* = 8.2, 4.1 Hz, 1H), 2.00 – 1.89 (m, 2H), 1.84 – 1.71 (m, 4H), 1.65 – 1.49 (m, 8H) ppm.

¹³C NMR (101 MHz, CDCl₃): δ 131.7, 128.3, 127.5, 124.4, 95.6, 80.6, 31.8, 30.9,

27.6, 25.6, 24.7 ppm.

This compound was previously reported¹⁴.

Compound 20



Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 1:1) afforded 33.1 mg (82%).

Physical State: colorless oil.

 $R_f = 0.40$ (petroleum ether/ethyl acetate = 1:1).

¹**H NMR (400 MHz, CDCl₃):** δ 7.33 – 7.28 (m, 2H), 7.13 – 7.07 (m, 2H), 4.43/4.23 (s, 2H), 3.11/3.03 (s, 3H), 2.34/2.33 (s, 3H), 2.20/2.11 (s, 3H) ppm.

¹³C NMR (126 MHz, CDCl₃): δ 170.7, 170.4, 138.9, 138.5, 131.7, 131.7, 129.2,

129.1, 119.7, 119.2, 84.7, 83.8, 83.5, 82.5, 41.2, 36.8, 35.2, 33.4, 21.8, 21.5 ppm.

HRMS (**ESI-TOF**): calculated for C₁₃H₁₅NO [M+Na]⁺: 224.1046, found: 224.1045.

Compound 21



Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 1:1) afforded 37.6 mg (77%).

Physical State: colorless oil.

 $R_f = 0.45$ (petroleum ether/ethyl acetate = 1:1).

¹**H NMR (400 MHz, CDCl₃):** δ 7.39 – 7.29 (m, 4H), 4.44/4.23 (s, 2H), 3.11/3.03 (s, 3H), 2.20/2.11 (s, 3H), 1.30/1.29 (s, 9H) ppm.

¹³C NMR (126 MHz, CDCl₃): δ 170.7, 170.3, 152.0, 151.7, 131.6, 131.5, 125.4, 125.3, 119.8, 119.3, 84.7, 83.8, 83.5, 82.5, 52.9, 49.1, 41.2, 36.8, 35.2, 33.4, 31.2,

31.2, 21.8, 21.6 ppm.

HRMS (ESI-TOF): calculated for $C_{16}H_{21}NO [M+Na]^+$: 266.1516, found: 266.1512.

Compound 22



Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 1:1) afforded 38.1 mg (86%).

Physical State: colorless oil.

 $R_f = 0.39$ (petroleum ether/ethyl acetate = 1:1).

¹**H NMR (400 MHz, CDCl₃):** δ 7.44 (dt, J = 7.5, 2.3 Hz, 1H), 7.41 – 7.35 (m, 1H), 7.29 – 7.15 (m, 2H), 4.51/4.30 (s, 2H), 3.16/3.06 (s, 3H), 2.22/2.13 (m, 3H) ppm.

¹³C NMR (126 MHz, CDCl₃): δ 170.8, 170.5, 136.2, 136.1, 133.5, 133.5, 129.8, 129.5, 129.4, 129.3, 126.6, 126.5, 122.7, 122.3, 89.7, 88.6, 81.5, 80.7, 41.3, 36.8, 35.3, 33.5, 21.8, 21.6 ppm.

HRMS (**ESI-TOF**): calculated for $C_{12}H_{12}CINO [M+Na]^+$: 244.0500, found: 244.0501.

Compound 23



Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 1:1) afforded 41.9 mg (79%).

Physical State: colorless oil.

 $R_f = 0.45$ (petroleum ether/ethyl acetate = 1:1).

¹**H NMR (400 MHz, CDCl₃):** δ 7.48 – 7.40 (m, 2H), 7.30 – 7.24 (m, 2H), 4.43/4.24 (s, 2H), 3.12/3.04 (s, 3H), 2.20/2.13 (s, 3H) ppm.

¹³C NMR (101 MHz, CDCl₃): δ 170.6, 170.5, 133.3, 133.2, 131.8, 131.6, 123.0,

122.7, 121.8, 121.2, 85.5, 84.4, 83.6, 82.6, 41.2, 36.8, 35.4, 33.5, 21.8, 21.6 ppm.

HRMS (**ESI-TOF**): calculated for $C_{12}H_{12}BrNO$ [M+Na]⁺: 287.9995, found: 287.9991.

Compound 24



Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 1:1) afforded 41.2 mg (98%).

Physical State: colorless oil.

 $R_f = 0.40$ (petroleum ether/ethyl acetate = 1:1).

¹**H NMR (400 MHz, CDCl₃):** δ 7.44 – 7.33 (m, 2H), 7.04 – 6.91 (m, 2H), 4.41/4.22 (s, 2H), 3.10/3.02 (s, 3H), 2.18/2.10 (s, 3H) ppm.

¹³C NMR (126 MHz, CDCl₃): δ 170.6, 170.4, 163.7, 163.5, 161.7, 161.5, 133.8, 133.7, 133.7, 133.6, 118.9, 118.8, 118.4, 118.3, 115.8, 115.7, 115.6, 115.5, 84.0, 84.0, 83.5, 82.9, 82.5, 41.1, 36.7, 35.3, 33.4, 21.7, 21.5 ppm.

¹⁹**F NMR (471 MHz, CDCl₃):** δ -110.3, -110.9 ppm.

HRMS (**ESI-TOF**): calculated for C₁₂H₁₂FNO [M+Na]⁺: 228.0796, found: 228.0794.

Compound 25

Ac N Мe CO₂Me

Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 1:1) afforded 16.7 mg (34%).

Physical State: colorless oil.

 $R_f = 0.25$ (petroleum ether/ethyl acetate = 1:1).

¹**H NMR (400 MHz, CDCl₃):** δ 8.08 – 7.81 (m, 2H), 7.57 – 7.34 (m, 2H), 4.44/4.25 (s, 2H), 3.89/3.88 (s, 3H), 3.11/3.02 (s, 3H), 2.19/2.11 (s, 3H) ppm.

¹³C NMR (126 MHz, CDCl₃): δ 170.6, 170.4, 166.5, 166.4, 131.8, 131.7, 130.0, 129.7, 129.6, 129.5, 127.5, 126.9, 87.4, 86.2, 83.9, 82.9, 52.3, 52.3, 41.2, 36.8, 35.4, 33.4, 21.7, 21.6 ppm.

HRMS (**ESI-TOF**): calculated for C₁₄H₁₅NO₃ [M+Na]⁺: 268.0945, found: 268.0942.

Compound 26



Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (dichloromethane/acetone = 10:1) afforded 30.3 mg (52%).

Physical State: colorless oil.

 $R_f = 0.60$ (dichloromethane/acetone = 10:1).

¹**H NMR (400 MHz, CDCl₃):** δ 7.58 – 7.18 (m, 4H), 4.42/4.23 (s, 2H), 3.10/3.02 (s, 3H), 2.18/2.10 (s, 3H) ppm.

¹³C NMR (126 MHz, CDCl₃): δ 170.6, 170.5, 136.1, 136.0, 135.3, 135.2, 132.2, 132.0, 131.9, 131.9, 128.5, 128.4, 123.2, 123.2, 85.2, 85.0, 83.1, 82.7, 79.3, 79.1, 51.1, 50.8, 41.2, 36.8, 35.3, 33.5, 21.8, 21.6 ppm.

HRMS (**ESI-TOF**): calculated for $C_{14}H_{12}BrNO$ [M+Na]⁺: 311.9995, found: 311.9991.

Compound 27

Me Me Ν Ac

Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (dichloromethane/acetone = 5:1) afforded 26.8 mg (45%).

Physical State: colorless oil.

 $R_f = 0.42$ (dichloromethane/acetone = 5:1).

¹**H NMR (400 MHz, CDCl₃):** δ 7.49 – 7.45 (m, 1H), 7.40 – 7.31 (m, 2H), 7.25 – 7.19 (m, 1H), 4.43/4.23 (s, 4H), 3.11/3.03 (s, 6H), 2.19/2.12 (d, 6H) ppm.

¹³C NMR (126 MHz, CDCl₃): δ 170.6, 170.4, 135.1, 135.0, 131.9, 131.8, 131.6, 131.5, 128.5, 128.4, 123.3, 123.1, 122.7, 122.6, 85.2, 85.0, 84.1, 83.9, 83.7, 83.6, 82.8, 82.6, 41.2, 36.8, 35.3, 33.4, 21.8, 21.6 ppm.

HRMS (ESI-TOF): calculated for C₁₈H₂₀N₂O₂ [M+Na]⁺: 319.1417, found: 319.1419.

Compound 28

Ac、 Мe TIPS

Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 2:1) afforded 35.8 mg (67%).

Physical State: colorless oil.

 $R_f = 0.30$ (petroleum ether/ethyl acetate = 2:1).

¹**H NMR (400 MHz, CDCl₃):** δ 4.28/4.05 (s, 2H), 3.06/2.98 (s, 3H), 2.15/2.08 (s, 3H), 1.04 (s, 21H) ppm.

¹³C NMR (126 MHz, CDCl₃): δ 170.7, 170.3, 102.4, 101.4, 86.2, 85.1, 41.5, 36.9, 34.9, 33.3, 21.9, 21.5, 18.7, 18.7, 11.3, 11.2 ppm.

HRMS (**ESI-TOF**): calculated for $C_{15}H_{29}NOSi$ [M+Na]⁺: 290.1911, found: 290.1912.

Compound 29

Ac N ≪_НеМе Мe

Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 2:1) afforded 23.7 mg (50%).

Physical State: colorless oil.

 $R_f = 0.42$ (petroleum ether/ethyl acetate = 2:1).

¹**H NMR (400 MHz, CDCl₃):** δ 4.17/3.96 (t, *J* = 2.2 Hz, 2H), 3.02/2.94 (s, 3H), 2.17 – 2.11 (m, 2H), 2.12/2.06 (s, 3H), 1.50 – 1.41 (m, 2H), 1.24 (s, 12H), 0.89 – 0.83 (m, 3H) ppm.

¹³C NMR (126 MHz, CDCl₃): 170.8, 170.4, 85.4, 84.4, 74.7, 74.0, 53.7, 51.9, 48.2, 41.7, 41.6, 40.8, 36.4, 35.0, 33.2, 32.0, 29.8, 29.6, 29.5, 29.4, 29.3, 29.2, 29.2, 29.0, 28.9, 28.8, 28.7, 28.5, 28.0, 22.8, 21.8, 21.5, 18.8, 18.7, 14.2 ppm.

HRMS (**ESI-TOF**): calculated for C₁₅H₂₇NO [M+Na]⁺: 260.1985, found: 260.1983.

Compound 30



Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (ethyl acetate) afforded 48.5 mg (61%).

Physical State: white solid.

 $R_f = 0.55$ (ethyl acetate).

¹**H NMR** (**500 MHz**, **CDCl**₃): δ 5.72 (s, 1H), 4.25/4.07 (d/s, *J* = 5.0 Hz, 2H), 3.04/2.95 (s, 3H), 2.47 – 2.18 (m, 6H), 2.13/2.08 (s, 3H), 2.05 – 1.48 (m, 8H), 1.48 – 1.21 (m, 4H), 1.18 (s, 3H), 1.08 – 0.89 (m, 2H), 0.87/0.86 (s, 3H) ppm.

¹³C NMR (126 MHz, CDCl₃): δ 199.7, 199.6, 171.3, 171.1, 170.6, 170.5, 124.0, 124.0, 88.3, 87.2, 80.9, 80.0, 79.8, 79.7, 53.7, 53.6, 50.3, 50.1, 47.0, 46.9, 40.7, 39.1, 39.0, 38.7, 38.7, 36.4, 36.3, 36.3, 35.8, 35.3, 34.1, 34.0, 33.4, 32.9, 32.8, 32.8, 31.6, 31.6, 29.8, 23.2, 21.8, 21.6, 20.8, 20.8, 17.5, 12.9 ppm.

HRMS (**ESI-TOF**): calculated for C₂₅H₃₅NO₃ [M+Na]⁺: 420.2510, found: 420.2511.



Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (ethyl acetate) afforded 42.9 mg (49%).

Physical State: colorless oil.

 $R_f = 0.41$ (ethyl acetate).

¹**H NMR (400 MHz, CDCl₃):** δ 7.85/7.85 (s 1H), 7.50/7.47 (d, J = 2.2 Hz, 1H), 7.11 – 7.02 (m, 2H), 6.96 – 6.85 (m, 2H), 4.82 – 4.70 (m, 3H), 4.27 – 4.02 (m, 2H), 3.01/2.94 (s, 3H), 2.12/2.08 (s, 3H), 1.63 (d, J = 6.8 Hz, 3H) ppm.

¹³C NMR (101 MHz, CDCl₃): δ 171.5, 171.4, 170.6, 170.5, 154.9, 151.4, 151.3, 148.4, 147.3, 147.3, 145.8, 140.3, 140.2, 129.8, 128.8, 125.2, 125.0, 122.5, 122.4, 122.4, 116.3, 116.2, 116.2, 82.7, 81.6, 78.1, 77.0, 73.1, 53.2, 52.9, 40.6, 36.3, 35.3, 33.4, 21.7, 21.5, 18.8, 18.6 ppm.

¹⁹**F NMR (471 MHz, CDCl₃):** δ -134.3 ppm.

HRMS (ESI-TOF): calculated for $C_{21}H_{20}ClFN_2O_5$ [M+Na]⁺: 457.0937, found: 457.0938.

Compound 32



Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 1:1) afforded 24.6 mg (65%).

Physical State: colorless oil.

 $R_f = 0.45$ (petroleum ether/ethyl acetate = 1:1).

¹H NMR (400 MHz, CDCl₃): δ 7.44 – 7.17 (m, 5H), 6.56 – 6.40 (m, 1H), 6.21 – 6.07 (m, 1H), 4.06/4.15 (dd, J = 6.0, 1.5 Hz, 2H), 2.99/2.98 (s, 3H), 2.14/2.13 (s, 3H) ppm.
¹³C NMR (126 MHz, CDCl₃): δ 171.0, 170.7, 136.7, 136.2, 132.9, 131.9, 128.8,

128.7, 128.1, 127.8, 126.5, 126.5, 124.7, 123.8, 52.8, 49.4, 35.6, 33.7, 22.0, 21.5 ppm. This compound was previously reported⁹.

Compound 33



Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 1:1) afforded 33.2 mg (62%).

Physical State: colorless oil.

 $R_f = 0.50$ (petroleum ether/ethyl acetate = 1:1).

¹**H NMR (400 MHz, CDCl₃):** δ 7.46 – 7.39 (m, 2H), 7.25 – 7.18 (m, 2H), 6.44 – 6.36 (m, 1H), 6.17 – 6.07 (m, 1H), 4.12/4.03 (dd, *J* = 5.8, 1.6 Hz, 2H), 2.98/2.96 (s, 3H), 2.12/2.12 (s, 3H) ppm.

¹³C NMR (101 MHz, CDCl₃): δ 170.9, 170.6, 135.6, 135.2, 131.9, 131.8, 131.5, 130.6, 128.0, 128.0, 125.6, 124.7, 121.5, 52.6, 49.4, 35.7, 33.6, 21.9, 21.4 ppm.

HRMS (**ESI-TOF**): calculated for $C_{12}H_{14}BrNO$ [M+Na]⁺: 290.0151, found: 290.0151.

Compound 34



Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 1:1) afforded 32.5 mg (59%).

Physical State: colorless oil.

 $R_f = 0.41$ (petroleum ether/ethyl acetate = 1:1).

¹**H NMR (400 MHz, CDCl₃):** δ7.43 – 7.32 (m, 2H), 7.21 – 7.10 (m, 2H), 6.53 – 6.40 (m, 1H), 6.20 – 6.05 (m, 1H), 4.13/4.05 (dd, *J* = 5.9, 1.7 Hz, 2H), 2.98/2.97 (s, 3H), 2.13/2.12 (s, 3H) ppm.

¹³C NMR (101 MHz, CDCl₃): δ 170.9, 170.6, 148.9, 148.7, 135.5, 135.0, 131.3, 130.3, 127.8, 127.7, 125.9, 125.0, 121.3, 121.2, 52.6, 49.4, 35.7, 33.6, 21.9, 21.4 ppm.
¹⁹F NMR (376 MHz, CDCl₃): δ -57.9 ppm.

HRMS (**ESI-TOF**): calculated for $C_{13}H_{14}F_3NO_2$ [M+Na]⁺: 296.0869, found: 296.0870.

Compound 35



Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 1:1) afforded 43.9 mg (88%).

Physical State: colorless oil.

 $R_f = 0.33$ (petroleum ether/ethyl acetate = 1:1).

¹**H NMR (400 MHz, CDCl₃):** δ 6.95 – 6.77 (m, 3H), 6.49 – 6.34 (m, 1H), 6.07 – 5.92 (m, 1H), 4.11/4.03 (dd, *J* = 6.1, 1.5 Hz, 2H), 3.95 – 3.80 (m, 6H), 2.98/2.96 (s, 3H), 2.13/2.11 (s, 3H) ppm.

¹³C NMR (101 MHz, CDCl₃): δ 170.9, 170.6, 149.2, 149.2, 149.2, 149.0, 132.7, 131.6, 129.8, 129.3, 122.7, 121.7, 119.8, 119.6, 111.3, 111.2, 109.0, 108.8, 56.1, 56.0, 56.0, 55.9, 52.7, 49.5, 35.6, 33.6, 22.0, 21.4 ppm.

This compound was previously reported¹⁶.

Compound 36



Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (ethyl acetate) afforded 54.6 mg (98%).

Physical State: colorless oil.

 $R_f = 0.61$ (ethyl acetate).

¹**H NMR (400 MHz, CDCl₃):** δ 7.01 – 6.88 (m, 3H), 6.49 – 6.37 (m, 1H), 6.13 – 6.02 (m, 1H), 4.12/4.04 (dd, *J* = 5.9, 1.5 Hz, 2H), 3.84/3.82 (s, 3H), 2.97/2.96 (s, 3H), 2.29/2.29 (s, 3H), 2.12/2.11 (s, 3H) ppm.

¹³C NMR (101 MHz, CDCl₃): δ 170.9, 170.6, 169.1, 169.1, 151.3, 151.2, 139.6, 139.4, 135.7, 135.3, 132.3, 131.1, 125.0, 124.1, 123.0, 122.9, 119.3, 119.0, 110.4, 110.0, 56.0, 55.9, 52.6, 49.4, 35.6, 33.6, 21.9, 21.4, 20.7 ppm.

HRMS (**ESI-TOF**): calculated for C₁₅H₁₉NO₄ [M+Na]⁺: 300.1207, found: 300.1206.

Compound 37



Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 1:1) afforded 24.5 mg (63%).

Physical State: colorless oil.

 $R_f = 0.56$ (petroleum ether/ethyl acetate = 1:1).

¹**H NMR (400 MHz, CDCl₃):** δ 7.20 – 7.08 (m, 1H), 7.01 – 6.88 (m, 2H), 6.64 – 6.54 (m, 1H), 6.02 – 5.90 (m, 1H), 4.10/4.01 (dd, *J* = 6.0, 1.6 Hz, 2H), 2.97/2.96 (s, 3H), 2.12/2.11 (s, 3H) ppm.

¹³C NMR (101 MHz, CDCl₃): δ 170.9, 170.6, 141.8, 141.2, 127.6, 127.4, 126.2, 126.0, 125.7, 125.0, 124.7, 124.4, 124.3, 123.4, 52.4, 49.1, 35.6, 33.6, 21.9, 21.4 ppm. This compound was previously reported¹⁶.

Compound 38



Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 1:1) afforded 39.8 mg (75%).

Physical State: colorless oil.
$R_f = 0.43$ (petroleum ether/ethyl acetate = 1:1).

¹**H** NMR (400 MHz, CDCl₃): δ 7.44 – 7.13 (m, 10H), 6.04/6.01 (t, *J* = 6.7 Hz, 1H), 4.08/3.95 (d, *J* = 6.7 Hz, 2H), 2.91/2.87 (s, 3H), 2.08/1.97 (s, 3H) ppm.

¹³C NMR (101 MHz, CDCl₃): δ 170.6, 170.5, 145.4, 144.9, 141.6, 141.2, 139.1, 138.7, 129.8, 129.7, 128.6, 128.4, 128.4, 128.3, 127.9, 127.6, 127.5, 127.4, 127.3, 124.4, 123.3, 49.9, 46.2, 35.6, 33.3, 21.9, 21.4 ppm.

This compound was previously reported¹⁵.

Compound 39



Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 1:1) afforded 32.8 mg (81%).

Physical State: colorless oil.

 $R_f = 0.47$ (petroleum ether/ethyl acetate = 1:1).

¹**H NMR (400 MHz, CDCl₃):** δ 7.48 – 7.24 (m, 5H), 5.37 (dd, J = 7.3, 1.3 Hz, 1H), 5.12 (t, J = 1.2 Hz, 1H), 3.51 – 3.33 (m, 2H), 2.91 (s, 3H), 2.81 – 2.73 (m, 2H), 2.02/1.91 (s, 3H) ppm.

¹³C NMR (101 MHz, CDCl₃): δ 170.5, 170.5, 145.8, 144.8, 140.5, 140.0, 128.7, 128.5, 128.0, 127.6, 126.1, 126.0, 115.0, 114.0, 49.8, 47.8, 37.0, 34.4, 33.2, 33.1, 22.0, 21.1 ppm.

HRMS (ESI-TOF): calculated for C₁₃H₁₇NO [M+Na]⁺: 226.1203, found: 226.1202.

Compound 40



Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 1:1) afforded 38.4 mg (81%).

Physical State: colorless oil.

 $R_f = 0.44$ (petroleum ether/ethyl acetate = 1:1).

¹**H** NMR (400 MHz, CDCl₃): δ 7.41 – 7.25 (m, 4H), 5.35/5.33 (d, 1.0 Hz, 1H), 5.11/5.11 (q, J = 1.1 Hz, 1H), 3.42/3.34 (dd, J = 8.3, 6.7 Hz, 2H), 2.91/2.89 (s, 3H), 2.77 – 2.66 (m, 2H), 2.01/1.91 (s, 3H) ppm.

¹³C NMR (101 MHz, CDCl₃): δ 170.6, 170.5, 144.6, 143.6, 138.9, 138.5, 133.9, 133.5, 128.9, 128.6, 127.4, 127.3, 115.6, 114.5, 49.7, 47.7, 37.0, 34.3, 33.3, 33.0, 22.0, 21.2 ppm.

HRMS (**ESI-TOF**): calculated for $C_{13}H_{16}CINO [M+Na]^+$: 260.0813, found: 260.0811.

Compound 41



Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 1:1) afforded 45.5 mg (90%).

Physical State: colorless oil.

 $R_f = 0.49$ (petroleum ether/ethyl acetate = 1:1).

¹**H NMR (400 MHz, CDCl₃):** δ 7.94 – 7.77 (m, 4H), 7.65 – 7.41 (m, 3H), 5.53/5.52 (d, J = 1.1 Hz, 1H), 5.22/5.21 (d, J = 1.2 Hz, 1H), 3.57 – 3.37 (m, 2H), 2.94/2.91 (s, 3H), 2.90 – 2.85 (m, 2H), 2.03/1.91 (s, 3H) ppm.

¹³C NMR (101 MHz, CDCl₃): δ 170.6, 170.6, 145.6, 144.5, 137.6, 137.1, 133.5, 133.4, 133.0, 132.9, 128.5, 128.4, 128.2, 128.1, 127.7, 127.6, 126.6, 126.3, 126.3, 126.0, 124.8, 124.7, 124.4, 124.3, 115.6, 114.6, 49.9, 48.0, 37.2, 34.4, 33.3, 33.1, 22.0, 21.2 ppm.

HRMS (ESI-TOF): calculated for C₁₇H₁₉NO [M+Na]⁺: 276.1359, found: 276.1360.

Compound 42

Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 2:1) afforded 22.0 mg (53%).

Physical State: colorless oil.

 $R_f = 0.36$ (petroleum ether/ethyl acetate = 2:1).

¹**H NMR (400 MHz, CDCl₃):** δ 5.64 – 5.61 (m, 1H), 5.48/5.43 (d, *J* = 1.8 Hz, 1H), 3.54/3.51 (t, *J* = 7.0 Hz, 2H), 3.02/2.91 (s, 3H), 2.65 (t, *J* = 6.7 Hz, 2H), 2.12/2.05 (s, 3H) ppm.

¹³C NMR (101 MHz, CDCl₃): δ 170.8, 170.8, 131.4, 129.8, 119.8, 118.8, 49.2, 46.9, 40.6, 39.7, 37.5, 33.5, 22.0, 21.4 ppm.

HRMS (ESI-TOF): calculated for C₇H₁₂BrNO [M+Na]⁺: 227.9995, found: 227.9997.

Compound 43



Following **Procedure H** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 2:1) afforded 25.9 mg (55%).

Physical State: colorless oil.

 $R_f = 0.41$ (petroleum ether/ethyl acetate = 2:1).

¹**H NMR (400 MHz, CDCl₃):** δ 6.81 – 6.67 (m, 1H), 4.96 – 4.80 (m, 2H), 3.58 – 3.28 (m, 2H), 2.97/2.90 (s, 3H), 2.79 – 2.40 (m, 3H), 2.40 – 2.17 (m, 4H), 2.06/2.04 (s, 3H), 1.77/1.75 (dt, *J* = 2.7, 1.4 Hz, 3H) ppm.

¹³C NMR (101 MHz, CDCl₃): δ 199.7, 199.2, 170.5, 170.3, 148.2, 147.4, 144.7, 144.2, 135.7, 135.5, 111.8, 111.1, 50.2, 46.8, 43.4, 43.4, 41.4, 41.0, 36.4, 33.5, 32.8, 31.8, 31.6, 30.0, 29.8, 22.0, 21.3, 15.8 ppm.

HRMS (**ESI-TOF**): calculated for C₁₄H₂₁NO₂ [M+Na]⁺: 258.1465, found: 258.1461.

Compound 47



Following **Procedure L** on 0.20 mmol scale. Purification by column chromatography (petroleum ether/ethyl acetate = 1:1) afforded 38.4 mg (65%).

Physical State: colorless oil.

 $R_f = 0.38$ (petroleum ether/ethyl acetate = 1:1).

¹**H NMR (400 MHz, CDCl₃):** δ 7.47 – 7.30 (m, 7H), 6.97 – 6.86 (m, 2H), 5.06/5.06 (s, 2H), 4.43/4.23 (s, 2H), 3.12/3.04 (s, 3H), 2.21/2.12 (s, 3H) ppm.

¹³C NMR (101 MHz, CDCl₃): δ 170.6, 170.3, 159.0, 158.8, 136.6, 136.5, 133.3, 133.2, 128.7, 128.6, 128.1, 128.1, 127.5, 115.1, 114.9, 114.8, 114.6, 114.6, 114.5, 84.4, 83.5, 82.8, 81.8, 70.0, 70.0, 41.2, 36.8, 35.1, 33.3, 21.7, 21.5 ppm.

HRMS (**ESI-TOF**): calculated for C₁₉H₁₉NO₂ [M+Na]⁺: 316.1308, found: 316.1307.

Quantum Yield Measurement

1. Determination of the light intensity at 452 nm:

According to the standard procedure for iron oxalate actinometry¹⁷ and the works by Yoon and co-workers¹⁸, the photon flux of the LED (λ_{max} = 452 nm) was first determined by standard ferrioxalate actinometry. For this, a 10 mL 0.15 M solution of ferrioxalate was prepared by dissolving potassium ferrioxalate hydrate (0.737 g) in H₂SO₄ (10 mL of a 0.05 M solution). A 20 mL buffered solution of 1, 10phenanthroline was prepared by dissolving 1, 10- phenanthroline (20 mg) and sodium acetate (4.5 g) in H₂SO₄ (20 mL of a 0.5 M solution). Both solutions were stored in the dark. To determine the photon flux of the LED, the ferrioxalate solution (2.0 mL) was placed in a cuvette and irradiated for 10 seconds at λ_{max} = 452 nm. After irradiation, the phenanthroline solution (0.35 mL) was added to the cuvette and the mixture was stirred in the dark for 1.0 h to allow all the ferrous ions to be coordinated by phenanthroline. The absorption of the solution was measured at 510 nm. A non-irradiated sample was also prepared identically and the absorption at 510 nm was also measured. Each sample preparation and measurements were repeated two more times. The average of the absorption of the irradiated and non-irradiated samples were determined and used for the calculation of photon flux.

$$\operatorname{mol} Fe^{2+} = \frac{V \times \Delta A \ (510 \ nm)}{l \times \varepsilon}$$

Where V is the total volume (0.00235 L) of the solution after addition of phenanthroline, ΔA is the difference in absorption at 510 nm between the irradiated and non-irradiated solutions, l is the path length (1.00 cm), and ε is the molar absorptivity of the ferrioxalate actinometer at 510 nm (11,100 L mol⁻¹ cm⁻¹). The photon flux can be calculated based on the following equation:

photon flux =
$$\frac{mol \ Fe^{2+}}{\Phi \times t \times f}$$

Where Φ is the quantum yield for the ferrioxalate actinometer (0.92 for a 0.15 M solution at $\lambda = 452 \text{ nm}$)¹⁷, *t* is the irradiation time (10 s), and *f* is the fraction of light absorbed at $\lambda = 452 \text{ nm}$. This value is calculated using the following equation where

A(452 nm) is the absorption of the ferrioxalate solution at 452 nm. The absorbance of the above ferrioxalate solution at 452 nm was measured to be 2.6328.

$$f = 1 - 10^{-A(452 \text{ nm})}$$

The average photon flux was thus calculated to be 4.48×10^{-8} einsteins s⁻¹

2. Determination of the reaction quantum yield:

Uranyl nitrate hexahydrate (8.0 mg, 8 mol%), 2-(2-pyridyl)benzimidazole (pbi) (3.9 mg, 10 mol%), (bromoethynyl)benzene (36.2 mg, 0.2 mmol, 1.0 equiv.) and cyclododecane (8.4 mg, 0.25 equiv., internal standard) were dissolved in N,N-dimethylacetamide (2 mL). The mixture was placed in a tube with a stirring bar. After that, the tube was exposed to two 60 W blue LEDs at room temperature After every 500 s, an aliquot of 20 μ L was taken out from this solution to monitor the yield by GC-FID. From the time vs yield curve, an initial product formation rate of 1.19×10^{-2} was determined. This will give a product formation rate of 2.38×10^{-8} mol sec⁻¹.



The reaction quantum yield (Φ) was determined with the following formula: $\Phi = \frac{\text{mole of product formation rate}}{\text{photon flux} \times f}$

Where, *f* is the fraction of light absorbed at $\lambda_{max} = 452$ nm by the reaction mixture. An absorption spectrum gave an *A*(452 nm) value of 0.3449, indicating that the fraction of absorbed light (*f*) is 0.5480.

$$\Phi = \frac{2.38 \times 10^{-8}}{4.481 \times 10^{-8} \times 0.5480} = 0.969$$

The reaction quantum yield (Φ) was thus determined to be $\Phi = 0.969$ (96.9%). Thus, a radical chain pathway may be ruled out.

References

- S. Nicolai, C. Piemontesi and J. Waser, A Palladium-Catalyzed Aminoalkynylation Strategy towards Bicyclic Heterocycles: Synthesis of (±)-Trachelanthamidine, *Angew. Chem. Int. Ed.*, 2011, **50**, 4680–4683.
- G. Cai, Z. Zhou, W. Wu, B. Yao, S. Zhang and X. Li, Pd-Catalyzed C(sp 3)–C(sp 2) cross-coupling of Y(CH 2 SiMe 3) 3 (THF) 2 with vinyl bromides and triflates, *Org. Biomol. Chem.*, 2016, 14, 8702–8706.
- 3 G. Zhang, R.-X. Bai, C.-H. Li, C.-G. Feng and G.-Q. Lin, Halogenation of 1,1-diarylethylenes by N-halosuccinimides, *Tetrahedron*, 2019, **75**, 1658–1662.
- 4 C. B. Tripathi and S. Mukherjee, Catalytic Enantioselective Iodoetherification of Oximes, *Angew. Chem. Int. Ed.*, 2013, **52**, 8450–8453.
- 5 A. Srikrishna and P. Hemamalini, Chiral synthons from carvone. Part 4. Radical cyclization strategies to bridged systems. Synthesis of bicyclo[3.2.1]octan-3-ones from (S)-carvone, *J. Org. Chem.*, 1990, 55, 4883–4887.
- J. E. Spangler, Y. Kobayashi, P. Verma, D.-H. Wang and J.-Q. Yu, α -Arylation of Saturated Azacycles and N -Methylamines via Palladium(II)-Catalyzed C(sp 3)–H Coupling, *J. Am. Chem. Soc.*, 2015, **137**, 11876–11879.
- 7 C. E. Jakobsche, A. Choudhary, S. J. Miller and R. T. Raines, R. T. n → π* Interaction and n)(π Pauli Repulsion Are Antagonistic for Protein Stability, J. Am. Chem. Soc., 2010, 132, 6651–6653.
- 8 K. Domino, C. Veryser, B. A. Wahlqvist, C. Gaardbo, K. T. Neumann, K. Daasbjerg, W. M. De Borggraeve and T. Skrydstrup, Direct Access to Aryl Bis(trifluoromethyl)carbinols from Aryl Bromides or Fluorosulfates: Palladium-Catalyzed Carbonylation, *Angew. Chem. Int. Ed.*, 2018, **57**, 6858–6862.

- S. Paul and J. Guin, Radical C(sp³)–H alkenylation, alkynylation and allylation of ethers and amides enabled by photocatalysis, *Green Chem.*, 2017, 19, 2530–2534.
- 10 J. Zhang, P. Li and L. Wang, KOAc-promoted alkynylation of α-C–H bonds of ethers with alkynyl bromides under transition-metal-free conditions, *Org Biomol Chem*, 2014, **12**, 2969–2978.
- 11 J.-J. Wu, Y. Li, H.-Y. Zhou, A.-H. Wen, C.-C. Lun, S.-Y. Yao, Z. Ke and B.-H. Ye, Copper-Catalyzed Carbamoylation of Terminal Alkynes with Formamides via Cross-Dehydrogenative Coupling, ACS Catal., 2016, 6, 1263–1267.
- 12 R.-Y. Zhang, L.-Y. Xi, L. Zhang, S. Liang, S.-Y. Chen and X.-Q. Yu, Metal-free alkynylation of α-C–H bonds of ethers with ethynylbenziodoxolones, *RSC Adv*, 2014, 4, 54349–54353.
- 13 J. Gong and P. L. Fuchs, Alkynylation of C-H Bonds via Reaction with Acetylenic Triflones, *J. Am. Chem. Soc.*, 1996, **118**, 4486–4487.
- 14 Y. Uenoyama, T. Fukuyama, K. Morimoto, O. Nobuta, H. Nagai and I. Ryu, Trifluoromethyl-Radical-Mediated Carbonylation of Alkanes Leading to Ethynyl Ketones, *Helv. Chim. Acta*, 2006, **89**, 2483–2494.
- 15 D.-L. Kong, L. Cheng, H.-R. Wu, Y.-X. Li, D. Wang and L. Liu, A metal-free yne-addition/1,4-aryl migration/decarboxylation cascade reaction of alkynoates with Csp3–H centers, *Org. Biomol. Chem.*, 2016, **14**, 2210–2217.
- 16 H. Yan, L. Lu, G. Rong, D. Liu, Y. Zheng, J. Chen and J. Mao, Functionalization of Amides via Copper-Catalyzed Oxyalkylation of Vinylarenes and Decarboxylative, *J. Org. Chem.*, 2014, **79**, 7103–7111.
- C. G. Hatchard and C. A. Parker, A new sensitive chemical actinometer II.
 Potassium ferrioxalate as a standard chemical actinometer, *Proc. R. Soc. Lond. Ser. Math. Phys. Sci.*, 1956, 235, 518–536.
- 18 M. A. Cismesia and T. P. Yoon, Characterizing chain processes in visible light photoredox catalysis, *Chem. Sci.*, 2015, **6**, 5426–5434.

NMR Spectra

Supplementary Figure 5. Compound **3** ¹H NMR in CDCl₃

7.43 7.42 7.42 7.44 7.39 7.39 7.39 7.32 7.32 7.32 7.32 7.32 7.32 7.32 7.32	7.30 7.30 7.29 7.29 7.29 7.27 7.27 7.27 7.27 7.27	4.24 3.11 3.03	2.20
		1 52	- 52



Supplementary Figure 6. Compound **3**¹³C NMR in CDCl₃



240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -5 f1 (ppm)

Supplementary Figure 7.Compound **4** ¹H NMR in CDCl₃

8.17	8.06	7.43	7.43	7.43	7.42	7.41	7.41	7.41	7.35	7.34	7.34	7.33	7.33	7.32	7.31	7.31	7.30	7.30	7.30	7.29	7.28	4.39	4.23	3.08	3.00
1	1	5	4	4	2	2	2	_	-	-	_			-		-	-	_	-	_	-	-	2	_	_



Supplementary Figure 8. Compound 4¹³C NMR in CDCl₃



0 0 0 0 0 4 0 4

:50 240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -{ f1 (ppm)

Supplementary Figure 9. Compound 5¹H NMR in CDCl₃







Supplementary Figure 10. Compound 5¹³C NMR in CDCl₃



50 240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -{ f1 (ppm)

Supplementary Figure 11. Compound **6** ¹H NMR in CDCl₃



Supplementary Figure 12. Compound 6¹³C NMR in CDCl₃

— 172.5

131.8 128.7 122.1	83.8 83.5	34.6	26.4
	\vee		



Supplementary Figure 13. Compound 7¹H NMR in CDCl₃





Supplementary Figure 14. Compound 7¹³C NMR in CDCl₃

240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -5 f1 (ppm)

Supplementary Figure 15. Compound 8¹H NMR in CDCl₃ $<^{4.26}_{4.25}$ --- 2.02 Ac N H 1.81_天 2.71注 1.00-2.17-≖ 3.07--2 -1 -2 -3 -4 6 f1 (ppm) 3 16 15 14 13 12 11 10 8 7 5 4 1 0 9

Supplementary Figure 16. Compound 8¹³C NMR in CDCl₃



240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -5 f1 (ppm)

Supplementary Figure 17. Compound 9¹H NMR in CDCl₃



4.49 4.49 4.48

Supplementary Figure 18. Compound 9¹³C NMR in CDCl₃



:50 240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 f1 (ppm)



Supplementary Figure 19. Compound 10¹H NMR in CDCl₃

Supplementary Figure 20. Compound 10¹³C NMR in CDCl₃



240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -5 f1 (ppm)



Supplementary Figure 21. Compound 11¹H NMR in CDCl₃

Supplementary Figure 22. Compound 11 ¹³C NMR in CDCl₃



240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -5 f1 (ppm)

Supplementary Figure 23. Compound 12 ¹H NMR in CDCl₃



- 7.32 - 7.32 - 7.30 - 7.30 - 7.29 - 7.28 - 7.28 - 7.28

2.66 2.77 2.67 2.67 2.66



Supplementary Figure 24. Compound 12 ¹³C NMR in CDCl₃



Supplementary Figure 25. Compound **12** ³¹P NMR in CDCl₃



140 120 100 80 60 40 20 0 -20 -40 -60 -80 -100 -120 -140 -160 -180 -200 -220 -240 f1 (ppm) Supplementary Figure 26. Compound 13 ¹H NMR in CDCl₃



Supplementary Figure 27. Compound 13¹³C NMR in CDCl₃

133.06 131.67 122.99 121.04	88.75 82.87	58.58 52.37 50.34	32.59 28.13 22.36
SZ SZ		1.51	215





240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -5 f1 (ppm)



Supplementary Figure 29. Compound 14¹³C NMR in CDCl₃ \sim 131.9 < 128.3 < 128.3 < 123.2 _____29.9 ____27.7 ^tBu₀ 250 240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -4

fl (ppm)

Supplementary Figure 30. Compound 15 ¹H NMR in CDCl₃

7.45 7.23 7.45 7.23 7.45 7.23 7.45 7.23 7.45 7.23 <t



Supplementary Figure 31. Compound 15¹³C NMR in CDCl₃

131.8 128.4 128.3 122.9	89.2 84.6	68.7 68.1	33.5	25.6
141		\sim		



:50 240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 f1 (ppm)

Supplementary Figure 32. Compound 16¹H NMR in CDCl₃




Supplementary Figure 33. Compound 16¹³C NMR in CDCl₃

2.0 2.4 2.1	N 4	ு வ வ வ
5 5 <u>5</u> 5	86 84	70 66 65
	17	



:50 240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -{ f1 (ppm)

Supplementary Figure 34. Compound 17¹H NMR in CDCl₃



Supplementary Figure 35. Compound 17¹³C NMR in CDCl₃







240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -5 f1 (ppm)

Supplementary Figure 36. Compound 18¹H NMR in CDCl₃



Supplementary Figure 37. Compound 18¹³C NMR in CDCl₃



240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -5 f1 (ppm)

Supplementary Figure 38. Compound 19¹H NMR in CDCl₃



Supplementary Figure 39. Compound **19**¹³C NMR in CDCl₃



240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -5 f1 (ppm)



S80

Supplementary Figure 41. Compound 20¹³C NMR in CDCl₃







Supplementary Figure 42. Compound 21¹H NMR in CDCl₃



Supplementary Figure 43. Compound 21¹³C NMR in CDCl₃

50 240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -{ f1 (ppm) Supplementary Figure 44. Compound 22 ¹H NMR in CDCl₃

7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	3.16 3.06	2.22 2.13
		- 57



Supplementary Figure 45. Compound 22 ¹³C NMR in CDCl₃



50 240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 f1 (ppm) Supplementary Figure 46. Compound 23 ¹H NMR in CDCl₃

7,247 7,447 7,454 7,454 7,454 7,444 7,444 7,444 7,447 7,247 7,27 7,2	4.43 4.24	3.12 3.04	2.20 2.13
	11	52	- 52



Supplementary Figure 47. Compound 23¹³C NMR in CDCl₃



240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -5 f1 (ppm)

Supplementary Figure 48. Compound 24 ¹H NMR in CDCl₃

7.39 7.37 7.37 7.37 7.37 7.37 7.37 7.37	4.41 4.22	3.10 3.02	2.18 2.10
	11	52	- \2



Supplementary Figure 49. Compound 24¹³C NMR in CDCl₃

170.6 170.4 163.7 163.5 161.7 161.7	133.8 133.7 133.7 133.7 1133.6 118.9 118.9 115.7 115.7 115.7	84.0 83.5 82.9 82.5	41.1 36.7 33.4	21.7 21.5
JYY	Y Y		5512	Y





50 240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -{ f1 (ppm)



20 10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 -2 f1 (ppm) Supplementary Figure 51. Compound 25 ¹H NMR in CDCl₃







Supplementary Figure 52. Compound 25¹³C NMR in CDCl₃



50 240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -{ f1 (ppm) Supplementary Figure 53. Compound 26¹H NMR in CDCl₃

7,266 7,756 7,756 7,756 7,756 7,757 7,757 7,757 7,757 7,757 7,757 7,757 7,757 7,757 7,757 7,757 7,757 7,757 7,757 7,757 7,757 7,756 7,756 7,756 7,756 7,756 7,756 7,756 7,756 7,756 7,756 7,756 7,756 7,756 7,756 7,756 7,756 7,756 7,756 7,756 7,757 7,756 7,757 7,756 7,757 7,756 7,757 7,756 7,757 7,756 7,757 7,756 7,7577 7,7577 7,7577 7,75777 7,75777 7,7577777777	3.11 3.10 3.02 3.02	2.19 2.18 2.10
VIII VIII VIII VIII VIII	YK	V





Supplementary Figure 54. Compound 26¹³C NMR in CDCl₃



240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -5 f1 (ppm)

Supplementary Figure 55. Compound 27 ¹H NMR in CDCl₃

7.47 7.46 7.36 7.37 7.35 7.35 7.35 7.33 7.33 7.33 7.33	4.43	3.11 3.03	2.19 2.12
	11	52	- 52





Supplementary Figure 56. Compound 27¹³C NMR in CDCl₃





50 240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -{ f1 (ppm)





Supplementary Figure 58. Compound 28¹³C NMR in CDCl₃



Supplementary Figure 59. Compound 29 ¹H NMR in CDCl₃



000000000000000000

96 94 94 94 0.87 0.85 0.84 Supplementary Figure 60. Compound 29¹³C NMR in CDCl₃



240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -5 f1 (ppm)



S101

Supplementary Figure 62. Compound 30¹³C NMR in CDCl₃



50 240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -{ f1 (ppm) Supplementary Figure 63. Compound 31 ¹H NMR in CDCl₃

7 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	2.12 2.08 1.64
	$-\gamma\gamma$





Supplementary Figure 64. Compound 31 ¹³C NMR in CDCl₃

171.5 171.6 170.6 170.6 170.6 170.6 170.5 170.5 170.2 125.2	82.7 81.6 78.1 77.0 73.1	53.2 52.9	40.6 36.3 35.3 33.4	21.7 21.5 18.8 18.6
	5172	\sim	5512	YK





240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -5 f1 (ppm)



10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 f1 (ppm) Supplementary Figure 66. Compound 32 ¹H NMR in CDCl₃

7.33 7.34 7.35 7.35 7.34 7.35 7.34 7.35 7.35 7.34 7.35 7.35 7.36 7.37 7.37 7.37 7.38 7.39 7.39 7.39 7.39 7.39 7.39 7.39 7.39 7.39 7.39 7.39 7.39 7.39 </tr





Supplementary Figure 67. Compound 32 ¹³C NMR in CDCl₃






Supplementary Figure 69. Compound 33 ¹³C NMR in CDCl₃



240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -5 f1 (ppm)

Supplementary Figure 70. Compound 34 ¹H NMR in CDCl₃

7.38 7.38 7.37	7.37 7.36	7.35	7.17	7.15	7.13 6.48	6.48	6.46 e.46	6.44 6.44	6.44	6.42	6.42	6.41	6.15	6.14 6.14	6.13	6.12	6.11	6.10	0.10	6.08	4.14	4.14	4.13	4.12	4.06	4.05	4.05	2.98	2.97	2.13	2.12
				_	- L - L						-	5	-	-		2	4	4			-		5	5	4	_	_	γ	/	$\langle \cdot \rangle$	1





Supplementary Figure 71. Compound 34 ¹³C NMR in CDCl₃

ရ ဖ	0 N 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	(a +		~ →
22	5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	0.4	3.0	0.4
55		¥ 5	88	ńй
\mathbf{Y}		11	- 17	\sim





240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -5 f1 (ppm) Supplementary Figure 72. Compound 34¹⁹F NMR in CDCl₃



10 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 f1 (ppm) Supplementary Figure 73. Compound 35 ¹H NMR in CDCl₃

0.000000000000000000000000000000000000	2.13 2.11
	\mathbf{Y}



Supplementary Figure 74. Compound 35¹³C NMR in CDCl₃



240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -5 f1 (ppm)

Supplementary Figure 75. Compound 36¹H NMR in CDCl₃

0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	0.00 0.42 0.44 0.44 0.44 0.44 0.44 0.44	6.07 6.06 6.06 6.05 6.05 6.03 6.03 7.4 11 7.4 11 7.1 2.03 8.4 0.4 7.1 2.29 7 2.29 7 2.29 5.23 9 6.03 7.12 7.12 2.29 7.23 5.23 6.03 7.12 7.12 7.12 7.12 7.12 7.12 7.12 7.12
		Y Y Y Y Y





Supplementary Figure 76. Compound 36¹³C NMR in CDCl₃

170.9 170.6 169.1 169.1	151.3 151.2 139.6 139.5 139.5 133.5 132.5 112.5 112.5 12.5 112.5 12.5 112.5 12.5	56.0 55.9 49.4	35.6 33.6	21.9 21.4 20.7
YZ		Y77	- 57	\leq



240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -5 f1 (ppm)

Supplementary Figure 77. Compound 37 ¹H NMR in CDCl₃

7.17 7.17 7.16 7.16 7.14 7.14 7.14 7.13 7.13 7.13 7.13 7.13 6.96 6.95	6.94 6.93 6.63 6.63 6.60 6.60 6.59 6.59 6.59	6.55 6.55 5.98 5.95 5.95 5.95 5.95 5.93	2.12 2.12 2.12 2.12 2.12 2.12 2.12 2.12





Supplementary Figure 78. Compound 37¹³C NMR in CDCl₃

< 170.9 170.6	$\begin{pmatrix} 141.8 \\ 127.6 \\ 127.6 \\ 127.6 \\ 127.6 \\ 125.7 \\ 125.7 \\ 125.7 \\ 125.7 \\ 125.7 \\ 123.4 \\ 12$	 / 35.6 / 33.6	$<_{21.9}^{21.9}$	



240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -5 f1 (ppm)



444 500	00 08 94	91	.08 97
××××××××××××××××××××××××××××××××××××××	4400	NN	~ ~
	YK	\sim	- 57



Supplementary Figure 80. Compound 38 ¹³C NMR in CDCl₃









Supplementary Figure 82. Compound 39¹³C NMR in CDCl₃

6.07 70.5	4 4 4 5 8 4 4 4 6 5 9 7 1 1 5 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	9.8 7.8	7.0 3.2 3.1	2.0
		44	m m m m	20
Y		- 17	SSP	- \2





240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -5 f1 (ppm) Supplementary Figure 83. Compound 40¹H NMR in CDCl₃







Supplementary Figure 84. Compound **40**¹³C NMR in CDCl₃

70.6 70.5	44.6 15.6 15.6 15.6 15.6 15.6 15.6 15.6 15	2.2	0.00	0.2
55		4 4	6666	N N
\vee	Share V	17	\sim	\sim





240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -5 f1 (ppm) Supplementary Figure 85. Compound 41 ¹H NMR in CDCl₃





Supplementary Figure 86. Compound 41¹³C NMR in CDCl₃

1170 6 1145 6 1145 6 1133 7 1133 7 1133 9 1133 9 1128 6 1128 6 11	49.9 48.0	37.2 34.4 33.3 33.1	22.0 21.2
	17	SSP	\mathbb{N}





Supplementary Figure 87. Compound 42 ¹H NMR in CDCl₃

0.64 0.63 0.63 0.63 0.63	62 62 64 64 64 64 64 64 64 64 64 64 64 64 64	8.56 8.57 8.56 8.57 8.57 8.57 8.56 8.57 8.56 8.56 7.55 7.55 7.55 7.55 7.55 7.55 7.55 7



Supplementary Figure 88. Compound 42¹³C NMR in CDCl₃

131.44 129.78	119.75 118.84	49.15 46.90 33.72 33.46	22.03 21.44
17	NZ	11/12/	\sim



 $<^{170.78}_{170.76}$



240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -5 f1 (ppm)

Supplementary Figure 89. Compound 43 ¹H NMR in CDCl₃

4 4 6 6 6 6 6 7 7 6 6 6 6 6 6 6 6 6 6 6	





Supplementary Figure 90. Compound 43 ¹³C NMR in CDCl₃

NN	9.0	047070	× -	
စ်စ်	o o	00 P 4 4 0 0	\leftarrow	<u>v</u> ¤44404n°¤¤¤00¤0n°
<u>6</u> 6	22	444400	7 7	000000000000000000000000000000000000000
i Cir	i Ci		i Ci	
X	Y		Y	





240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -5 f1 (ppm)

Supplementary Figure 91. Compound 47 ¹H NMR in CDCl₃

$\begin{array}{c} 7.44\\ 7.42\\ 7.42\\ 7.42\\ 7.42\\ 7.42\\ 7.42\\ 7.42\\ 7.33\\$	5.06 4.43	4.23 3.12 3.04	2.21
	$Y \downarrow$	1 52	



Supplementary Figure 92. Compound **47**¹³C NMR in CDCl₃

170.6 170.3	159.0 158.0 136.5 136.5 133.3 128.1 128.1 128.1 114.6 114.6 114.6 114.6 114.5	84.4 83.5 82.8 81.8 70.0 70.0	41.2 36.8 35.1 33.3 21.7 21.7
$\mathbf{\nabla}$			



240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -5 f1 (ppm)